• Versiti Blood Utilization Guidelines - Preface
• Versiti Blood Utilization Guidelines - Red Blood Cells
• Versiti Blood Utilization Guidelines - Plasma
• Versiti Blood Utilization Guidelines - Apheresis Platelets
• Versiti Blood Utilization Guidelines - Cryoprecipitated AHF
• Versiti Blood Utilization Guidelines - Modifications of Blood Components
• Versiti Blood Utilization Guidelines - Autologous and Directed Units
• Versiti Blood Utilization Guidelines - Factor Concentrates
• Versiti Blood Utilization Guidelines - Summary of Thresholds for Blood Component Transfusion

• Versiti Pediatric Blood Utilization Guidelines - Preface
• Versiti Pediatric Blood Utilization Guidelines - Cryoprecipitated AHF
• Versiti Pediatric Blood Utilization Guidelines- Red Blood Cells (Infants <4 months)

• Massive Transfusion Protocol Development
• PBM Perspective Part 1 - The Clinical Perspective
• PBM Perspective Part 2 - The Economic Perspective
• PBM Perspective Part 3 - The Operational Perspective

• Fresh Blood for Adults – Does it Matter?
• In the Era of Leukoreduction, are CMV-Seronegative Tested Blood Products Beneficial?
• RBC Transfusions for Neonates: Are RBCs Stored in Additive Solutions Safe?

• Creating a Maximum Surgical Blood Ordering Schedule
• Guidelines for Use of Group O Neg RBCs
• O Negative RBC Tips for Optimizing Utilization
• O Negative Tips from Your Coach
• O Negative Tips from Your Coach Case Studies
• O Negative Tips from Coach Case Study Answers
• O Negative Hospital and Blood Center Roles in Utilization

• Myths and Realities of Plasma Use

• Apheresis Platelet Products Offered by Versiti: A Side by Side Comparison
• Pathogen Reduced Platelets
• Low Yield Platelets: Safety and Efficacy for Patient Care
• FAQs: Pathogen Reduced Apheresis Platelets & Use in Pediatric and Neonatal Patients
• FAQs: Apheresis Platelet Products Offered by Versiti to Meet the FDA Bacterial Mitigation Guidance

• Acceptable ABO/RhD Substitutions for Blood Products - ADULTS
• Acceptable ABO/RhD Substitutions for Blood Products - PEDIATRICS
• Example Guidelines for Transfusion and Anemia Management During Blood Product Shortages
• Managing Inventory During Blood Shortage
• Recommendations to Clinicians for Transfusion Practice During Blood Product Shortage

• Acute Transfusion Reactions: Signs, Symptoms, and Nursing Actions
• Delayed Transfusion Reactions: Signs, Symptoms, and Nursing Actions
• Tips for Transfusionists: Acceptable ABO/RhD Type for Commonly Transfused Blood Products
• Tips for Transfusionists: Checking Hemoglobin after Transfusion
• Tips for Transfusionists: Needle Gauge for Transfusion
• Tips for Transfusionists: Premedications Before a Blood Transfusion: Where's the Evidence?
• Tips for Transfusionists: Recommended Blood Adminstration Tubing

• Getting a Transfusion
• Preparing for Elective Surgery

• Low Titer Group O Whole Blood - Implications for Practice
• Blood Components for Massively Bleeding Trauma or Surgical Patients

• ABC Blood Bulletin Cryoprecipitate (Cryo) and Alternatives October 2022
• ABC Blood Bulletin Directed Donations and COVID-19 mRNA Vaccinated Blood Donors March 2023
• ABC Blood Bulletin Consignee Notification February 2024
• ABC Blood Bulletin Futility and Potentially Inappropriate Treatment in Massive Transfusion October 2024
• ABC Blood Bulletin Neonatal Transfusion Support - Modifications and Preparations of Red Cell Transfusions - A Case Study May 2025

ABO specific or compatible cryoprecipitate should be selected for pediatric or neonatal transfusions due to small blood volume of these patients. Single units of group AB cryoprecipitate are available from Versiti for neonates.

For adults (or patients >45 kg) any ABO group is acceptable. (See Acceptable ABO/RhD Substitutions for Blood Products – Adults.) Facilities may decide to limit number of units to avoid adverse effects from excessive volume of incompatible plasma.

During transport, the maximum time platelet products may be without agitation is 30 hours and temperature should be as close as possible to 20-24°C.¹

During storage, platelet products require continuous gentle agitation at 20-24°C.1 This agitation ensures proper gas exchange for aerobic respiration of the platelets and maintaining pH above 6.2.

In the hospital or laboratory setting, situations may occur where a platelet product is briefly stored without agitation (e.g. operating or procedure room). Studies on the handling of platelet products post manufacturing generally show that interruption in agitation for up to 24 hours does not adversely affect the quality of the platelets. At the end of 5 days, invitro markers are within acceptable limits and pH remains above 6.2. Platelets stored in plasma appear to withstand interruption in agitation better than platelets stored in platelet additive solution unless the additive solution contains bicarbonate or phosphate to regulate the pH. In addition, fewer platelets and larger plasma volumes tolerate the interruptions better, presumably due to less acidic conditions and lower risk for irreversible change to the platelets.^2,3

Platelets fared better with shorter, multiple interruptions than a prolonged interruption (i.e., three 8-hour periods without agitation versus one 24-hour period). With shorter interruptions, the impact of the reduced gas exchange is lower and more tolerable for the platelets.3 With apheresis platelet shelf life being 7 days, it is particularly important to limit the duration of each individual interruption of agitation.

References:

1. Galel SA, et al. AABB Standards for Blood Banks and Transfusion Services, 34th Edition, effective April 1, 2024,
2. Hunter S, et al. The effect of interruption of agitation on platelet quality during storage for transfusion. Transfusion 2001;41:809-814.
3. Thomas S. Platelets: handle with care. Transfusion Medicine 2016;26:330–338.

Per CAP TRM.42100 (10-24-2022) and AABB BBTS 7.5.2.4 (33rd edition), when a hemolytic transfusion reaction occurs that is suspected to be related to an attribute of the donor or the blood component, the blood supplier must be notified.

Example: Suspected hemolysis due to passive ABO antibodies from ABO-nonspecific platelet transfusion (Group A recipient receives Group O or Group B apheresis platelet).

Yes. 

The irradiation indicator placed on the unit at the time of irradiation is an internal visual quality control check. The ISBT label is the permanent label for the product. The ISBT component code indicates the product has been irradiated and acceptable for patients who require this blood component modification.

Manufacturers assign a maximum limit for platelet concentration and volume for their apheresis platelet bags to maintain proper gas exchange and optimize platelet viability during storage. When these limits are exceeded but there is insufficient quantity of platelets to manufacture 2 separate platelet products, the single product is stored in a double bag configuration to assure adequate gas exchange to maintain pH above 6.2 and acceptable platelet quality at end of shelf-life.

If a hospital transfusion service desires to combine the two bags, this should be done just prior to issue or release of the platelet product for transfusion. While there is no guidance from the manufacturers or accrediting agencies on an acceptable expiration after combining the bags, an outdate of 24 hours from the time of pooling or the original product expiration, whichever is sooner, is customarily used. This is likely based on the manufacturer’s allowance for the platelets to remain in a single bag for up to 24 hours after collection before the required storage in a double bag.¹ Although it would be an uncommon occurrence, if a closed system could not be maintained during the pooling, the expiration of the final product would then be 4 hours from time of pooling per AABB Standards for Blood Banks and Transfusion Services (STD 5.1.9).²

References:

1. Terumo BCT Recommendations for the ELP Storage Bag. 2017 Terumo BCT, Inc. / PN 306640415E.
2. Galel SA, et al. AABB Standards for Blood Banks and Transfusion Services, 34th Edition, effective April 1, 2024.